CJC-1295 + Ipamorelin benefits and uses

What has been measured in people

All human data on the parts of this blend come from studies that measured hormone levels or recovery of gut function after surgery.¹²

• CJC-1295 with DAC, 2006 phase 1 trial (healthy adults aged 21 to 61): one injection raised mean growth hormone 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9 to 11 days.⁴
• The same program with repeat doses: when two or three doses were spaced 1 or 2 weeks apart, mean IGF-1 stayed above baseline for up to 28 days.⁴¹
• CJC-1295 with DAC, 2006 (12 healthy men aged 20 to 40): a week after one injection, trough growth hormone was 7.5 times higher, mean growth hormone 46% higher and IGF-1 45% higher, with the normal pulse pattern kept and IGF-1 never above the upper limit of normal.⁵¹
• IV ipamorelin, 1999 (healthy men, 8 per dose level): each infusion produced a single growth hormone peak at about 0.67 hours (about 40 minutes), falling to very low levels by 6 hours.⁶²
• IV ipamorelin after bowel surgery, 2014 phase 2 (114 adults): median time to the first tolerated meal was 25.3 hours versus 32.6 hours with placebo, a difference that was not statistically significant (p = 0.15).⁷
• A larger phase 2 surgery trial of ipamorelin (320 enrolled, completed May 2014) has posted no results.⁸

None of these studies tested the blend, and none measured muscle, fat, sleep, skin or healing of an injury.¹²²¹²²

Findings in animals and cells

• Bone growth, rats: ipamorelin injected under the skin for 15 days raised bone lengthening from 42 to 44, 50 and 52 micrometers a day as the dose rose, with more weight gain; total IGF-1 did not change.⁹
• Bone mineral, rats: 12 weeks of ipamorelin by pump increased bone mineral content in the tibia and spine, in step with body weight gain, through larger bones rather than denser bone.¹⁰
• Steroid-treated rats: over 3 months, adding ipamorelin preserved calf muscle strength and raised the rate of bone formation on the bone surface four-fold compared with the steroid alone.¹¹
• Body fat, mice: ipamorelin increased fat pad weight relative to body weight, and secretagogue treatment (ipamorelin or GHRP-6) raised food intake in mice with normal growth hormone; the authors concluded the fat gain did not depend on growth hormone.¹²
• Hormone selectivity, pigs: ipamorelin released growth hormone while ACTH and cortisol rose no more than with GHRH, even at over 200 times its half-maximal dose; GHRP-6 and GHRP-2 raised both.¹³
• CJC-1295 with DAC, GHRH-knockout mice: injections every 1 to 3 days for 5 weeks gave longer leg bones and more lean mass than in untreated knockout mice.¹
• The blend: a 2026 primer for sports physicians says CJC-1295 combined with ipamorelin improved maximum tetanic tension, a measure of muscle force, in rodents with steroid-induced muscle loss.¹⁴ The matching study, in steroid-treated rats in 2001, gave ipamorelin alone, and FDA traces CJC-1295 to a 2005 report, so this result should not be credited to the blend.¹¹¹

A 2026 review of peptide therapies notes that many unapproved peptides show favorable tissue repair and metabolic results in animals, while rigorous human safety data are scarce.¹⁵

What sources say by goal

Muscle and strength

No human study of either peptide or the blend measured muscle mass or strength.¹² Reviews from 2020 and 2026 describe clinical efficacy data for growth hormone secretagogues as lacking or limited, and a 2026 scoping review found claimed musculoskeletal benefits of these peptides unsubstantiated by human trials.¹⁶¹⁷²³ Peptides and muscle growth maps the wider research.

Fat loss

No human data show fat loss with this blend or with either peptide.¹² The animal signal runs the other way: ipamorelin raised fat pad weight in mice, and secretagogue treatment raised their food intake.¹² Tesamorelin, a different GHRH analog, is FDA-approved only to reduce excess abdominal fat in adults with HIV and lipodystrophy.¹⁸ The wider topic is covered in Peptides and weight loss.

Sleep

The published human studies measured hormone levels or gut recovery, not sleep.⁴⁵⁶⁷ In the phase 2 surgery trial, insomnia was reported more often with ipamorelin (10.7%) than with placebo (5.2%).² See Peptides and sleep.

Recovery and healing

The one published human recovery trial, after bowel surgery, missed its main goal; a larger trial posted no results, and development for that use was stopped.⁷⁸² No study has tested these peptides for tendon, muscle or wound healing in people.²¹⁵ See Peptides and healing and recovery.

Skin and hair

Websites claim collagen, skin and hair effects, but FDA found no study of any CJC-1295 form in people with a disease or condition, and none of the published studies measured skin or hair.¹ A PubMed search for ipamorelin with hair or alopecia returns no records.¹⁹

Men, testosterone and women

Most people in the CJC-1295 studies (87%) were men, and their main outcomes were growth hormone and IGF-1.¹⁴ A 2026 sexual-medicine review found that secretagogues reliably raise those hormones, but evidence for better sexual function, physical performance or quality of life remains limited.¹⁷ In pigs, ipamorelin did not change LH or FSH, the pituitary hormones that drive testosterone production.¹³ The ipamorelin bone studies were done in female rats, not women.⁹¹⁰ Related hubs: Peptides and men's health and Peptides and testosterone.

Blood sugar

Here the evidence points to a possible risk, not a benefit. High blood sugar at discharge was more common with ipamorelin (14.3%) than with placebo (8.6%) after surgery, and FDA lists glucose intolerance and diabetes among the known risks of raised growth hormone shown on approved growth hormone labels.²¹

How to read this evidence

A 2026 review puts CJC-1295 without DAC in its lowest evidence tier, for compounds with no peer-reviewed human studies at all; most other GHRH analogs and ghrelin mimetics rank higher, with phase 1 or 2 studies but no controlled efficacy data on performance.³ Synergy between the two drug classes has been shown only with other peptides, for example GHRH plus GHRP-6 in 18 healthy men in 1990.²⁰ Side effects and safety warnings are on What is CJC-1295 + Ipamorelin?, and the doses these studies used are on CJC-1295 + Ipamorelin dosage.